Alzchem Group AG: management transactions · Germany · BaFin

About Alzchem Group AG

Alzchem Group AG is a German specialty chemicals company listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in the regulated market (Prime Standard) in Germany. Headquartered in Trostberg, Bavaria, the company is embedded in the long-established Bavarian Chemical Triangle and operates four production sites in Germany, an additional plant in Sweden, and sales operations in the United States, China, and the United Kingdom. This footprint reflects a vertically integrated, export-oriented industrial model focused on technically demanding niches rather than commodity-scale volumes. The group’s roots lie in decades of industrial development around nitrogen chemistry and chemical intermediates. Today, Alzchem reports through three business segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The main value-creation engine is the Specialty Chemicals segment, which includes well-known brands and products such as Creapure®, Creamino®, Bioselect®, DYHARD®, Dormex®, and Nitroguanidine. Its offering spans human and animal nutrition, PCR test precursors, pharmaceutical raw materials, agriculture-related solutions, metallurgy, infrastructure applications, and selected industrial and defense uses. The Basics & Intermediates segment supplies chemical intermediates for internal use and external customers, reinforcing the group’s industrial integration. Alzchem’s competitive position is built on three pillars: a strong focus on niche specialty markets, a “Verbund production” setup that reduces dependence on external suppliers, and close geographic proximity among its Bavarian plants, which supports manufacturing synergies, R&D efficiency, and operational flexibility. In a still-challenging European chemical environment, this positioning has allowed the company to preserve and improve profitability. For 2024, Alzchem reported external sales of EUR 554.2 million and EBITDA of EUR 105.3 million. For 2025, the company said it delivered another record year, underscoring the resilience of its business model. Recent milestones include the strong earnings progression in 2024, supported by higher-margin specialty chemicals, as well as Alzchem’s inclusion in the SDAX on October 2, 2024. Into 2025/2026, the group also announced a growth investment program, pointing to continued confidence in its long-term niche-market strategy. For French-speaking investors, Alzchem stands out as a mid-cap industrial specialty chemicals name with a solid German manufacturing base and global commercial reach.